Free Trial

Insmed (INSM) Stock Price, News & Analysis

Insmed logo
$83.61 -0.22 (-0.26%)
Closing price 02/20/2025 04:00 PM Eastern
Extended Trading
$83.56 -0.05 (-0.06%)
As of 02/20/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Insmed Stock (NASDAQ:INSM)

Key Stats

Today's Range
$79.50
$84.28
50-Day Range
$65.25
$83.83
52-Week Range
$21.92
$84.28
Volume
2.29 million shs
Average Volume
1.67 million shs
Market Capitalization
$14.96 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.86
Consensus Rating
Buy

Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Insmed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

INSM MarketRank™: 

Insmed scored higher than 75% of companies evaluated by MarketBeat, and ranked 280th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Insmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Insmed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Insmed's stock forecast and price target.
  • Earnings Growth

    Earnings for Insmed are expected to grow in the coming year, from ($5.42) to ($4.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Insmed is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Insmed is -15.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Insmed's valuation and earnings.
  • Percentage of Shares Shorted

    8.13% of the outstanding shares of Insmed have been sold short.
  • Short Interest Ratio / Days to Cover

    Insmed has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Insmed has recently decreased by 3.64%, indicating that investor sentiment is improving.
  • Dividend Yield

    Insmed does not currently pay a dividend.

  • Dividend Growth

    Insmed does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.13% of the outstanding shares of Insmed have been sold short.
  • Short Interest Ratio / Days to Cover

    Insmed has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Insmed has recently decreased by 3.64%, indicating that investor sentiment is improving.
  • News Sentiment

    Insmed has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Insmed this week, compared to 9 articles on an average week.
  • Search Interest

    11 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 38% compared to the previous 30 days.
  • MarketBeat Follows

    11 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,400,465.00 in company stock.

  • Percentage Held by Insiders

    Only 4.60% of the stock of Insmed is held by insiders.

  • Read more about Insmed's insider trading history.
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

Insmed Incorporated (NASDAQ:INSM) CFO Sells $1,471,439.82 in Stock
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Insmed (NASDAQ:INSM) Shares Gap Down Following Weak Earnings
Insmed reports Q4 EPS ($1.32), consensus ($1.16)
See More Headlines

INSM Stock Analysis - Frequently Asked Questions

Insmed's stock was trading at $69.04 at the beginning of the year. Since then, INSM stock has increased by 21.1% and is now trading at $83.61.
View the best growth stocks for 2025 here
.

Insmed Incorporated (NASDAQ:INSM) posted its earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by $0.15.

Insmed's top institutional shareholders include Vanguard Group Inc. (10.18%), Darwin Global Management Ltd. (7.24%), Price T Rowe Associates Inc. MD (7.10%) and Capital International Investors (3.98%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, Martina MD Flammer, Orlov S Nicole Schaeffer and Michael Alexander Smith.
View institutional ownership trends
.

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
2/20/2025
Today
2/21/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$90.86
High Stock Price Target
$107.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+8.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

Net Income
$-749,570,000.00
Net Margins
-252.01%
Pretax Margin
-251.01%

Debt

Sales & Book Value

Annual Sales
$305.21 million
Book Value
($2.32) per share

Miscellaneous

Free Float
170,673,000
Market Cap
$14.96 billion
Optionable
Optionable
Beta
1.11

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:INSM) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners